MA-ECHOSENS
21.6.2022 14:58:10 CEST | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan® portfolio of solutions, is pleased to announce its solutions will be included in 22 oral presentations and 157 posters that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings at EASL International Liver Congress™ 2022, June 22-26, 2022, London, United Kingdom. Echosens leaders will present the symposium “FibroScan® Solutions Bringing New Guidelines to Life,” 11 a.m.-12:30 p.m., Meeting Room N19, ExCel London Center, on June 23. Additionally, Echosens will offer “How to Improve Early Screening and Management of Chronic Liver Disease Outside Hospital Setting?” -- two demonstrations of FibroScan® GO, 3 p.m.-4 p.m. or 5:30 p.m.-6:30 p.m. on June 23 in Meeting Room N19, ExCel London.
“This very important meeting furthers the worldwide understanding of liver research, enhances the clinical practice of liver disorders and educates those interested in hepatology,” says Dominique Legros, Group CEO, Echosens. “FibroScan® , the non-invasive solution for comprehensive management of liver health, is recognized worldwide, validated by over 3,500 peer reviewed publications and 160 international guidelines and considered the most widely studied tool for point of care liver assessment.”
Echosens will be available at booth N°46 to discuss and demonstrate early detection with new FibroScan GO, diagnosing and monitoring with FibroScan Mini+ 430 and FibroScan Compact 530, advanced diagnosis and risk stratification with FibroScan Expert 630 live patient demonstration, and digital demonstrations of myFibroScan and Scores by Echosens.
Jon Gingrich, CEO, Echosens North America, adds, “We are thrilled by the global validation of FibroScan and broad consensus of the need for screening and early intervention to prevent advanced liver disease. FibroScan can more cost-effectively identify individuals who are asymptomatic and undiagnosed for liver damage, as well as provide metrics for monitoring changes in liver fat due to lifestyle modification.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005114/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026: Food Sovereignty, AI, Personalised Nutrition… Three Major Debates to Shape the Future of Food14.10.2026 09:35:00 CEST | Press release
More than just a major business event, SIAL Paris is also a forum for reflection, analysis and inspiration for the entire food sector. Over five days, several stages will bring together leaders, experts, manufacturers, retailers, researchers and entrepreneurs to analyse the sector’s transformations and, above all, to identify concrete courses of action. Food sovereignty, artificial intelligence, geopolitics, new consumption models, personalised nutrition and the transformation of the value chain: the 2026 edition offers a particularly rich programme, featuring conferences, keynote speeches, round-table discussions, pitches and case studies. SIAL Summits: three major events to understand today and prepare for tomorrow At the heart of this programme, the SIAL Summits, held in Hall 5A, offer three premium 2½-hour sessions dedicated to the strategic challenges reshaping the agri-food industry. Designed as genuine platforms for discussion and reflection, they will bring together experts and
UNPACK ’27: HOTELS.COM AFSLØRER DE REJSETRENDS, DER KOMMER TIL AT PRÆGE 202714.10.2026 09:00:00 CEST | Pressemeddelelse
Ny rapport fra Hotels.com identificerer fem rejsetrends, der vil komme til at præge 2027 lige fra efterspørgslen på små svipture og en genopblomstring af gotiske destinationer til næste års prognose for set-jetting. Hotels.com har i dag offentliggjort den årlige rapport Unpack ’27: The Trends in Travel™, der undersøger de destinationer, oplevelser og adfærdsmønstre, der forventes at præge rejsebranchen i 2027. Baseret på indsigter fra Hotels.com samt global rejseresearch og social listening afslører Unpack ‘27 de nye steder, der tiltrækker rejsende i 2027, og nogle overraskende ting, de foretager sig, når de først er ankommet. “At rejse handler om at skabe minder, og Unpack ‘27 afslører de destinationer og oplevelser, der præger netop de øjeblikke”, siger Ariane Gorin, CEO for Expedia Group. “I 2027 vil rejsende være mere bevidste i valget af deres næste eventyr og søge oplevelser, der er mere personlige og meningsfulde for dem. Vi gør det nemmere at opdage, planlægge og booke den rigt
Otometrics Launches Aurical® IQ – Delivering the First and Only Guided Workflow Enabling up to 51% Faster Fittings and 39% Improved Workflow Accuracy14.10.2026 09:00:00 CEST | Press release
Clinical evaluations demonstrated up to 51% faster fitting times for experienced clinicians and 39% improved workflow accuracy for newer clinicians; Aurical IQ also supports the NAL-NL3 Fitting System Otometrics, the Hearing & Balance division of Natus Sensory, today announced Aurical® IQ, the next generation of its trusted hearing aid fitting and verification platform. Combining the first and only Guided Workflow for hearing aid fitting and verification, support for the NAL-NL3 Fitting System and a redesigned Otosuite® software experience, Aurical IQ is designed to help hearing care professionals work more efficiently and follow best-practice fitting procedures with greater consistency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014023398/en/ Aurical IQ Guided Workflow provides structured, step-by-step guidance through the fitting and verification process, designed to make best-practice fitting easier to follow. A ne
NEURA Robotics Introduces Neuron AI: The Brain of the Physical World14.10.2026 08:29:00 CEST | Press release
Beyond vision: Neuron AI brings 3D vision, touch, audio, robot state and language together with memory in one Perception-Language-Action (PLA) model, so robots can react to what they cannot seeOne model, every body: Trained on real-world robot data, simulation-amplified data and human demonstrations, Neuron AI runs across five NEURA robot embodiments and their grippers and handsFrom skill to fleet: Customers fine-tune Neuron AI for their own tasks and deploy skills across robot fleets via the platform Neuraverse, with Time-to-Skill as the central measure of progressAI built in Germany: Developed and trained in-house in Metzingen, GermanyLive at NVIDIA GTC Berlin: NEURA’s humanoid 4NE1 will complete an eleven-minute laundry task, fully autonomous from start to finish NEURA Robotics (“NEURA”) today introduced Neuron AI, its multimodal foundation model for Physical AI. Combining 3D vision, touch, audio, robot state and language with memory, Neuron AI enables robots to act on information b
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering14.10.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Acquisition brings together two highly complementary, science-backed skincare brands ZO Skin Health’s premium daily multi-step regimens complement Alastin’s regenerative skincare portfolio primarily focused on peri-procedure support Transaction expands Galderma’s Dermatological Skincare portfolio and offering in the attractive, fast-growing physician-dispensed skincare segment1 Galderma’s unique Integrated Dermatology Strategy, global scale and omni-channel execution capabilities expected to support ZO Skin Health’s next phase of growth Acquisition of 100% of ZO Skin Health for an enterprise value of 1.5 billion USD, expected to be Core EPS neutral in the first full year following closing Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom